Drug Trial Radar · NCT02055157
A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia
Last checked: Nov 20, 2026Latest source record: Jan 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Jan 13, 2014
Primary completion
Oct 2, 2017
Study completion Oct 2, 2017
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Feb 5, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.
Conditions
- Achondroplasia
Interventions
BMN 111Drug
BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Summary of Adverse Events During Initial 6-Month PeriodTime frame: Up to Month 6 ± 7 Days
- Overall Summary of Adverse Events During Entire Study PeriodTime frame: Up to Month 25 ± 7 Days
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Children's Hospital & Research Center Oakland
Oakland, California
Harbor - UCLA Medical Center
Torrance, California
Ann and Robert H. Lurie Childrens Hospital of Chicago
Chicago, Illinois
Johns Hopkins McKusick - Institute of Genetic Medicine
Baltimore, Maryland
Vanderbilt University
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
Murdoch Children's Research Institute
Parkville, Victoria, Australia
Institut Necker
Paris, France
Guys & St. Thomas NHS Foundation Trust Evelina Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.